ClinicalTrials.gg
CompletedNCT01962441Updated Jun 20, 2017Results posted

SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection

A Phase 3 interventional study of SOF and RBV in Hepatitis C, sponsored by Gilead Sciences. Completed at 78 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-20.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
601
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing sofosbuvir in Hepatitis C — 1 open to participants now, 3 under way, none of them phase 3. Sofosbuvir · Hepatitis C.

Enrollment
6th of 94
601 · median 75
Started
2013
with 6 others
Phase 3
30 of 94
none open now
Registered
21st of 94
by date
Lead sponsor
30 of 94
Gilead Sciences

Among the 94 studies testing sofosbuvir in Hepatitis C, this one is the 6th largest by enrollment, is one of 7 that started in 2013, is one of 30 in phase 3, and was the 21st registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

1 of the 94 studies testing sofosbuvir in Hepatitis C is open now. Recruiting first, the newest first:

About sofosbuvir

Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing sofosbuvir in Hepatitis C, or all of them as a file.
02

Study summary

This study will assess the efficacy, safety, and tolerability of 16 or 24 weeks of sofosbuvir (Sovaldi®; SOF) + ribavirin (RBV), and 12 weeks of SOF+RBV+ pegylated interferon (Peg-IFN) in treatment-naive and treatment-experienced adults with chronic genotype 3 hepatitis C virus (HCV) infection, and treatment-experienced adults with cirrhosis and chronic genotype 2 HCV infection.

03

Conditions studied

  • Hepatitis C

Browse trials for

Keywords

  • 7977
  • GS-7977
  • PSI-7977
  • Sofosbuvir (SOF)
  • Pegylated Interferon (Peg-IFN)
  • Ribavirin (RBV)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female, age greater than or equal to 18 years.
  • Confirmed chronic infection.
  • Subjects will have cirrhosis status assessment; liver may be required.
  • Genotype 2 subjects must have cirrhosis of the liver to be eligible.
  • Treatment-naive or prior treatment failure to ≥12 weeks of an interferon- based regimen that was not discontinued prematurely due to an adverse event
  • Infection with HCV genotype 2 or 3 as determined at Screening
  • (BMI) greater than or equal to 18 kg/m\^2
  • Screening laboratory values within predefined thresholds.
  • Liver imaging (e.g., ultrasound) within 6 months of Baseline/Day 1 is required in cirrhotic patients to exclude hepatocellular carcinoma (HCC). In the event of intrahepatic lesions, triple phase CT scan or MRI should be performed to exclude HCC.
  • Subject must be of generally good health as determined by the Investigator.

Key Exclusion Criteria:

  • Prior use of any other inhibitor of the HCV nonstructural protein (NS)5B polymerase
  • Pregnant or nursing female or male with pregnant female partner
  • History of any other chronic liver disease.
  • or chronic virus (HBV) infection.
  • with the exception of certain resolved skin cancers.
  • Chronic use of systemically administered agents.
  • Clinically-relevant drug or alcohol abuse.
  • History of solid organ transplantation.
  • Current or prior history of clinical hepatic decompensation.
  • History of clinically-significant illness or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol.
  • Known to interferon, RBV, the study medicinal product, the metabolites, or formulation .

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
601 participants (actual)

Study arms

  • Experimental
    SOF+RBV 16 weeks

    SOF+RBV for 16 weeks

    Drug: SOF · Drug: RBV

  • Experimental
    SOF+RBV 24 weeks

    SOF+RBV for 24 weeks

    Drug: SOF · Drug: RBV

  • Experimental
    SOF+RBV+Peg-IFN 12 weeks

    SOF+RBV+Peg-IFN for 12 weeks

    Drug: SOF · Drug: RBV · Drug: Peg-IFN

  • Experimental
    Retreatment Substudy

    Participants from the SOF+RBV arms (16 weeks or 24 weeks) who experienced virologic failure on treatment, or during the posttreatment period at or before Posttreatment Week 24 may be eligible to enroll into the Retreatment Substudy to receive SOF+RBV+Peg-IFN for 12 weeks.

    Drug: SOF · Drug: RBV · Drug: Peg-IFN

Interventions

  • DrugSOF

    400 mg tablet administered orally once daily

    Also known as: Sovaldi®, GS-7977, PSI-7977

  • DrugRBV

    Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

  • 180 µg administered via subcutaneous injection once weekly

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)

    SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

    Time frame: Posttreatment Week 12

  2. Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)

    SVR4 and SVR 24 were defined as HCV RNA \< LLOQ at 4 and 24 weeks after stopping study treatment, respectively.

    Time frame: Posttreatment Weeks 4 and 24

  2. Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 8, 12, 16, 20, and 24

    Time frame: Weeks 1, 2, 4, 8, 12, 16, 20, and 24

  3. HCV RNA at Weeks 1, 2, 4, 8, and 12

    Time frame: Weeks 1, 2, 4, 8, and 12

  4. Change From Baseline in HCV RNA at Weeks 1, 2, 4, 8, and 12

    Time frame: Baseline; Weeks 1, 2, 4, 8, and 12

  5. Percentage of Participants Experiencing On-Treatment Virologic Failure

    On-treatment virologic failure was defined as: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)

    Time frame: Up to 24 weeks

  6. Percentage of Participants Experiencing Viral Relapse

    Viral relapse is defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.

    Time frame: Up to Posttreatment Week 24

07

Results

Posted Feb 5, 2016

Participant flow

Participants were enrolled at study sites in Europe, North America, Australia, and New Zealand. The first participant was screened on 24 September 2013. The last study visit occurred on 07 July 2016.

Randomized Period
Participant flow — Randomized Period
MilestoneSOF+RBV 16 Weeks, Then RetreatmentSOF+RBV 24 Weeks, Then RetreatmentSOF+RBV+Peg-IFN 12 Weeks
Started200201200
Completed190190189
Not completed101111
Withdrew: Randomized but never treated423
Withdrew: Lost to follow-up244
Withdrew: Withdrew consent332
Withdrew: Adverse event110
Withdrew: Death002
Withdrew: Protocol violation010
Retreatment Substudy
Participant flow — Retreatment Substudy
MilestoneSOF+RBV 16 Weeks, Then RetreatmentSOF+RBV 24 Weeks, Then RetreatmentSOF+RBV+Peg-IFN 12 Weeks
Started20100
Completed18100
Not completed200
Withdrew: Lack of efficacy100
Withdrew: Lost to follow-up100

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)

SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

Time frame:
Posttreatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
percentage of participantsSOF+RBV 16 WeeksSOF+RBV 24 WeeksSOF+RBV+Peg-IFN 12 Weeks
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)71.985.492.9
PrimaryPercentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
percentage of participantsSOF+RBV 16 WeeksSOF+RBV 24 WeeksSOF+RBV+Peg-IFN 12 Weeks
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event1.51.51.5
SecondaryPercentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)

SVR4 and SVR 24 were defined as HCV RNA \< LLOQ at 4 and 24 weeks after stopping study treatment, respectively.

Time frame:
Posttreatment Weeks 4 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
percentage of participantsSOF+RBV 16 WeeksSOF+RBV 24 WeeksSOF+RBV+Peg-IFN 12 Weeks
SVR473.085.995.9
SVR2471.984.493.4
SecondaryPercentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 8, 12, 16, 20, and 24
Time frame:
Weeks 1, 2, 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 8, 12, 16, 20, and 24
percentage of participantsSOF+RBV 16 WeeksSOF+RBV 24 WeeksSOF+RBV+Peg-IFN 12 Weeks
Week 114.820.125.9
Week 253.353.567.0
Week 486.691.997.4
Week 899.599.599.5
Week 12100.098.5100.0
Week 1699.099.5—
Week 20—99.5—
Week 24—100.0—
SecondaryHCV RNA at Weeks 1, 2, 4, 8, and 12
Time frame:
Weeks 1, 2, 4, 8, and 12
Reported as:
Mean · log10 IU/mL
HCV RNA at Weeks 1, 2, 4, 8, and 12
log10 IU/mLSOF+RBV 16 WeeksSOF+RBV 24 WeeksSOF+RBV+Peg-IFN 12 Weeks
Week 12.13 ± 0.6582.08 ± 0.7491.81 ± 0.576
Week 21.44 ± 0.4361.45 ± 0.4871.32 ± 0.342
Week 41.19 ± 0.1561.21 ± 0.2871.16 ± 0.085
Week 81.15 ± 0.0211.15 ± 0.1001.15 ± 0.000
Week 121.15 ± 0.0001.17 ± 0.3181.15 ± 0.000
SecondaryChange From Baseline in HCV RNA at Weeks 1, 2, 4, 8, and 12
Time frame:
Baseline; Weeks 1, 2, 4, 8, and 12
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Weeks 1, 2, 4, 8, and 12
log10 IU/mLSOF+RBV 16 WeeksSOF+RBV 24 WeeksSOF+RBV+Peg-IFN 12 Weeks
Week 1-4.18 ± 0.559-4.15 ± 0.664-4.46 ± 0.556
Week 2-4.86 ± 0.661-4.78 ± 0.714-4.96 ± 0.661
Week 4-5.11 ± 0.671-5.02 ± 0.735-5.12 ± 0.699
Week 8-5.16 ± 0.684-5.08 ± 0.708-5.12 ± 0.691
Week 12-5.15 ± 0.686-5.05 ± 0.788-5.12 ± 0.691
SecondaryPercentage of Participants Experiencing On-Treatment Virologic Failure

On-treatment virologic failure was defined as: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)

Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing On-Treatment Virologic Failure
percentage of participantsSOF+RBV 16 WeeksSOF+RBV 24 WeeksSOF+RBV+Peg-IFN 12 Weeks
Percentage of Participants Experiencing On-Treatment Virologic Failure01.50
SecondaryPercentage of Participants Experiencing Viral Relapse

Viral relapse is defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.

Time frame:
Up to Posttreatment Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Viral Relapse
percentage of participantsSOF+RBV 16 WeeksSOF+RBV 24 WeeksSOF+RBV+Peg-IFN 12 Weeks
Percentage of Participants Experiencing Viral Relapse26.712.34.6

Adverse events

Collected over Up to 24 weeks plus 30 days (Randomized Period) Up to 12 additional weeks plus 30 days (Retreatment Period). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomized Period: SOF+RBV 16 Weeks0/196 (0%)8/196 (4.1%)173/196 (88.3%)
Randomized Period: SOF+RBV 24 Weeks0/199 (0%)10/199 (5%)176/199 (88.4%)
Randomized Period: SOF+RBV+Peg-IFN 12 Weeks0/197 (0%)12/197 (6.1%)192/197 (97.5%)
Retreatment Period: SOF+RBV+Peg-IFN 12 Weeks0/30 (0%)1/30 (3.3%)29/30 (96.7%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventRandomized Period: SOF+RBV 16 WeeksRandomized Period: SOF+RBV 24 WeeksRandomized Period: SOF+RBV+Peg-IFN 12 WeeksRetreatment Period: SOF+RBV+Peg-IFN 12 Weeks
Musculoskeletal painMusculoskeletal and connective tissue disorders0/1960/1990/1971/30
Acute coronary syndromeCardiac disorders1/1960/1990/1970/30
PancreatitisGastrointestinal disorders1/1961/1990/1970/30
Chest painGeneral disorders1/1960/1990/1970/30
CellulitisInfections and infestations1/1960/1990/1970/30
ArthritisMusculoskeletal and connective tissue disorders1/1960/1990/1970/30
Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1960/1990/1970/30
DepressionPsychiatric disorders1/1960/1991/1970/30
Suicidal ideationPsychiatric disorders1/1960/1990/1970/30
Orthostatic hypotensionVascular disorders1/1960/1990/1970/30
Most frequent other events
Showing 10 of 49
Most frequent other events
EventRandomized Period: SOF+RBV 16 WeeksRandomized Period: SOF+RBV 24 WeeksRandomized Period: SOF+RBV+Peg-IFN 12 WeeksRetreatment Period: SOF+RBV+Peg-IFN 12 Weeks
FatigueGeneral disorders74/19683/19992/19718/30
HeadacheNervous system disorders61/19672/19970/19712/30
InsomniaPsychiatric disorders47/19656/19950/1972/30
NauseaGastrointestinal disorders32/19634/19950/1977/30
MyalgiaMusculoskeletal and connective tissue disorders12/19619/19933/1977/30
Influenza like illnessGeneral disorders7/1968/19939/1976/30
PyrexiaGeneral disorders5/1967/19929/1976/30
PruritusSkin and subcutaneous tissue disorders21/19624/19922/1976/30
RashSkin and subcutaneous tissue disorders24/19627/19939/1976/30
Decreased appetiteMetabolism and nutrition disorders13/19616/19935/1973/30

Baseline characteristics

Safety Analysis Set: participants with genotype 2 or 3 HCV infection who were randomized and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)SOF+RBV 16 WeeksSOF+RBV 24 WeeksSOF+RBV+Peg-IFN 12 WeeksTotal
Mean51 ± 9.749 ± 9.850 ± 10.250 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)SOF+RBV 16 WeeksSOF+RBV 24 WeeksSOF+RBV+Peg-IFN 12 WeeksTotal
Female627065197
Male134129132395
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)SOF+RBV 16 WeeksSOF+RBV 24 WeeksSOF+RBV+Peg-IFN 12 WeeksTotal
Hispanic or Latino55212
Not Hispanic or Latino188188191567
Not Disclosed36413
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)SOF+RBV 16 WeeksSOF+RBV 24 WeeksSOF+RBV+Peg-IFN 12 WeeksTotal
Black or African American2226
White162168165495
Asian29262580
American Indian/ Alaska Native/ First Nations2002
Hawaiian or Pacific Islander0123
Other0112
Not Disclosed1124
Region of Enrollment
Region of Enrollment(participants)SOF+RBV 16 WeeksSOF+RBV 24 WeeksSOF+RBV+Peg-IFN 12 WeeksTotal
New Zealand15121340
Canada21332983
United States29333193
United Kingdom868280248
Australia453944128
HCV Genotype
HCV Genotype(participants)SOF+RBV 16 WeeksSOF+RBV 24 WeeksSOF+RBV+Peg-IFN 12 WeeksTotal
Genotype 215171648
Genotype 3181182181544
IL28b Status
IL28b Status(participants)SOF+RBV 16 WeeksSOF+RBV 24 WeeksSOF+RBV+Peg-IFN 12 WeeksTotal
CC757378226
CT949598287
TT27312179
HCV RNA
HCV RNA(log10 IU/mL)SOF+RBV 16 WeeksSOF+RBV 24 WeeksSOF+RBV+Peg-IFN 12 WeeksTotal
Mean6.3 ± 0.686.2 ± 0.716.3 ± 0.696.3 ± 0.69

1 further baseline measures are reported on the registry.

08

Study locations

78 sites
  • Riverside, California 92501, United States
  • San Diego, California 92123, United States
  • San Francisco, California 94115, United States
  • Aurora, Colorado 80045, United States
  • Englewood, Colorado 80113, United States
  • Miami, Florida 33136, United States
  • Wellington, Florida 33414, United States
  • Marietta, Georgia 30060, United States
  • New Orleans, Louisiana 70121, United States
  • Boston, Massachusetts 02215, United States
  • Novi, Michigan 48377, United States
  • Saint Paul, Minnesota 55114, United States
  • Hillsborough, New Jersey 08844, United States
  • Newark, New Jersey 07102, United States
  • Binghamton, New York 13903, United States
  • New York, New York 10021, United States
  • Germantown, Tennessee 38138, United States
  • Nashville, Tennessee 37211, United States
  • Nashville, Tennessee 37212-1610, United States
  • Arlington, Texas 76012, United States
  • Austin, Texas 78705, United States
  • Norfolk, Virginia 23502, United States
  • Seattle, Washington 98101, United States
  • Camperdown, New South Wales 2050, Australia
  • Kogarah, New South Wales 2217, Australia
  • Westmead, New South Wales 2145, Australia
  • Brisbane, Queensland 4029, Australia
  • Greenslopes, Queensland 4120, Australia
  • Woolloongabba, Queensland 4102, Australia
  • Adelaide, South Australia 5000, Australia
  • Clayton, Victoria 3168, Australia
  • Fitzroy, Victoria 3065, Australia
  • Heidelberg, Victoria 3084, Australia
  • Melbourne, Victoria 3004, Australia
  • Nedlands Perth, Western Australia 6009, Australia
  • Calgary, Alberta T2N 4Z6, Canada
  • Edmonton, Alberta T6G 2B7, Canada
  • Vancouver, British Columbia V5Z 1M9, Canada
  • Vancouver, British Columbia V6Z 2C7, Canada
  • Vancouver, British Columbia V6Z 2K5, Canada
  • Winnipeg, Manitoba R3E 3P4, Canada
  • Hamilton, Ontario L8N 4A6, Canada
  • London, Ontario N6A 5A5, Canada
  • Ottawa, Ontario K1H 8L6, Canada
  • Toronto, Ontario M5T 2S8, Canada
  • Toronto, Ontario M6H 3M1, Canada
  • Montreal, Quebec H2X 3J4, Canada
  • Québec, Quebec G1V 4G2, Canada
  • Grafton, Auckland 1010, New Zealand
  • Grafton, Auckland 1023, New Zealand
  • Christchurch, Chatham Islands 8011, New Zealand
  • Hamilton, Waikato 3204, New Zealand
  • Wellington, 6021, New Zealand
  • Edgbaston, Birmingham B15 2TH, United Kingdom
  • Cambridge, Cambridgeshire CB2 0QQ, United Kingdom
  • London, LN E1 1BB, United Kingdom
  • London, LN SE5 9RS, United Kingdom
  • London, LN SW17 ORE, United Kingdom
  • London, LN W2 1NY, United Kingdom
  • Birmingham, B9 5SS, United Kingdom
  • Bradford, BD9 6RJ, United Kingdom
  • Dundee, DD1 9SY, United Kingdom
  • Edinburgh, EH16 4SA, United Kingdom
  • Edinburgh, EH4 2XU, United Kingdom
  • Frimley, GU46 6HU, United Kingdom
  • Glasgow, G12 0YN, United Kingdom
  • Glasgow, G4 0SF, United Kingdom
  • Leeds, LS9 7TF, United Kingdom
  • Liverpool, L7 8XP, United Kingdom
  • London, NW3 2QG, United Kingdom
  • London, SW10 9NH, United Kingdom
  • Manchester, M85RB, United Kingdom
  • Newcastle Upon Tyne, NE7 7DN, United Kingdom
  • Nottingham, NG7 2UH, United Kingdom
  • Oxford, OX3 9DU, United Kingdom
  • Plymouth, PL6 8DH, United Kingdom
  • Portsmouth, PO6 3LY, United Kingdom
  • Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, Barnes E, Brainard DM, Massetto B, Lin M, Han B, McHutchison JG, Subramanian GM, Cooper C, Agarwal K; BOSON Study Group. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015 Nov;149(6):1462-70. doi: 10.1053/j.gastro.2015.07.043. Epub 2015 Aug 4. PubMed 26248087 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Jan 2015, 15 months.

Results were first posted in Feb 2016, 1 year after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 15 months is above that.

Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2013
First posted
Oct 14, 2013
StartActual
Sep 24, 2013
Primary completionActual
Jan 7, 2015
CompletionActual
Jul 7, 2016
Results first posted
Feb 5, 2016
Last update
Jun 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01962441
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Oct 14, 2013
Start date
Sep 24, 2013
Primary completion
Jan 7, 2015
Completion
Jul 7, 2016
Results posted
Feb 5, 2016
Last update
Jun 20, 2017

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sofosbuvir · Ribavirin

Start the discussion